Does the media favor TTRX or MNOV?

In the previous week, Turn Therapeutics had 5 more articles in the media than MediciNova. MarketBeat recorded 8 mentions for Turn Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Turn Therapeutics' score of 0.50 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AMRN or MNOV?

MediciNova has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.38 -$38.80M -$0.99 N/A MediciNova $410K 224.49 -$12M -$0.21 N/A

Is AMRN or MNOV more profitable?

Amarin has a net margin of -14.56% compared to MediciNova's net margin of -1,168.70%. Amarin's return on equity of -0.20% beat MediciNova's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% MediciNova -1,168.70% -26.51% -24.39%

Does the media favor AMRN or MNOV?

In the previous week, MediciNova had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Amarin. MediciNova's average media sentiment score of 1.07 beat Amarin's score of 0.96 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZNTL or MNOV?

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for MediciNova. Zentalis Pharmaceuticals' average media sentiment score of 1.07 equaled MediciNova'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACB or MNOV?

MediciNova has a consensus price target of $8.33, suggesting a potential upside of 345.63%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media favor ACB or MNOV?

In the previous week, Aurora Cannabis had 6 more articles in the media than MediciNova. MarketBeat recorded 9 mentions for Aurora Cannabis and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Aurora Cannabis' score of 0.29 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRDL or MNOV?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Cardiol Therapeutics' score of 0.70 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MediciNova (MNOV) Competitors

$1.87 +0.06 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.87 +0.00 (+0.16%)

As of 07:56 PM Eastern

Compare

MNOV vs. TTRX, AMRN, ZNTL, ACB, and CRDL

Should you buy MediciNova stock or one of its competitors? MediciNova's main competitors and comparable companies include Turn Therapeutics (TTRX), Amarin (AMRN), Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediciNova compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

9.9% of MediciNova shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Turn Therapeutics has higher earnings, but lower revenue than MediciNova. Turn Therapeutics is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
MediciNova	$410K	224.49	-$12M	-$0.21	N/A

In the previous week, Turn Therapeutics had 5 more articles in the media than MediciNova. MarketBeat recorded 8 mentions for Turn Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Turn Therapeutics' score of 0.50 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics presently has a consensus target price of $9.00, indicating a potential downside of 33.09%. MediciNova has a consensus target price of $8.33, indicating a potential upside of 345.63%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Turn Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
MediciNova	-1,168.70%	-26.51%	-24.39%

Summary

MediciNova beats Turn Therapeutics on 11 of the 14 factors compared between the two stocks.

How does MediciNova compare to Amarin?

Amarin (NASDAQ:AMRN) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, MediciNova had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Amarin. MediciNova's average media sentiment score of 1.07 beat Amarin's score of 0.96 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Amarin has a net margin of -14.56% compared to MediciNova's net margin of -1,168.70%. Amarin's return on equity of -0.20% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
MediciNova	-1,168.70%	-26.51%	-24.39%

MediciNova has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.38	-$38.80M	-$0.99	N/A
MediciNova	$410K	224.49	-$12M	-$0.21	N/A

22.3% of Amarin shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amarin presently has a consensus target price of $13.00, suggesting a potential downside of 7.14%. MediciNova has a consensus target price of $8.33, suggesting a potential upside of 345.63%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

MediciNova beats Amarin on 11 of the 17 factors compared between the two stocks.

How does MediciNova compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
MediciNova	-1,168.70%	-26.51%	-24.39%

MediciNova has lower revenue, but higher earnings than Zentalis Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.72	-$137.06M	-$1.95	N/A
MediciNova	$410K	224.49	-$12M	-$0.21	N/A

Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

9.9% of MediciNova shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, suggesting a potential upside of 92.86%. MediciNova has a consensus price target of $8.33, suggesting a potential upside of 345.63%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for MediciNova. Zentalis Pharmaceuticals' average media sentiment score of 1.07 equaled MediciNova'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MediciNova beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

MediciNova has lower revenue, but higher earnings than Aurora Cannabis. MediciNova is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.00	-$88.13M	-$1.41	N/A
MediciNova	$410K	224.49	-$12M	-$0.21	N/A

Aurora Cannabis has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

In the previous week, Aurora Cannabis had 6 more articles in the media than MediciNova. MarketBeat recorded 9 mentions for Aurora Cannabis and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Aurora Cannabis' score of 0.29 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova has a consensus price target of $8.33, suggesting a potential upside of 345.63%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurora Cannabis has a net margin of -32.26% compared to MediciNova's net margin of -1,168.70%. Aurora Cannabis' return on equity of 4.37% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
MediciNova	-1,168.70%	-26.51%	-24.39%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MediciNova beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does MediciNova compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

MediciNova has higher revenue and earnings than Cardiol Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
MediciNova	$410K	224.49	-$12M	-$0.21	N/A

In the previous week, Cardiol Therapeutics had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 1.07 beat Cardiol Therapeutics' score of 0.70 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
MediciNova	-1,168.70%	-26.51%	-24.39%

Cardiol Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 402.51%. MediciNova has a consensus target price of $8.33, indicating a potential upside of 345.63%. Given Cardiol Therapeutics' higher possible upside, research analysts clearly believe Cardiol Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MediciNova beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.09M	$12.41B	$7.16B	$13.99B
Dividend Yield	N/A	2.64%	2.57%	11.70%
P/E Ratio	-8.90	653.40	213.39	20.92
Price / Sales	224.49	755.57	639.79	90.03
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	2.20	10.44	10.43	6.24
Net Income	-$12M	$2.84B	$3.49B	$358.08M
7 Day Performance	14.72%	-3.15%	-2.11%	-1.43%
1 Month Performance	42.75%	1.39%	0.64%	-2.71%
1 Year Performance	52.03%	3.96%	24.61%	8.46%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	2.2257 of 5 stars	$1.87 +3.3%	$8.33 +345.6%	+47.2%	$89.09M	$410K	N/A	10	Positive News Gap Up
TTRX Turn Therapeutics	1.5759 of 5 stars	$12.66 +29.2%	$8.00 -36.8%	N/A	$291.92M	N/A	N/A	2	News Coverage Analyst Upgrade Gap Down High Trading Volume
AMRN Amarin	1.0071 of 5 stars	$14.25 +4.5%	$13.00 -8.8%	-8.1%	$287.91M	$186.23M	N/A	360
ZNTL Zentalis Pharmaceuticals	3.4504 of 5 stars	$4.03 +1.0%	$6.75 +67.5%	+135.6%	$285.97M	N/A	N/A	160
ACB Aurora Cannabis	1.0537 of 5 stars	$3.87 -2.0%	N/A	-23.2%	$256.12M	$247.82M	N/A	1,028	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. TTRX, AMRN, ZNTL, ACB, and CRDL

How does MediciNova compare to Turn Therapeutics?

Summary

How does MediciNova compare to Amarin?

Summary

How does MediciNova compare to Zentalis Pharmaceuticals?

Summary

How does MediciNova compare to Aurora Cannabis?

Summary

How does MediciNova compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. TTRX, AMRN, ZNTL, ACB, and CRDL

How does MediciNova compare to Turn Therapeutics?

Do insiders & institutionals have more ownership in TTRX or MNOV?

Which has higher valuation and earnings, TTRX or MNOV?

Does the media favor TTRX or MNOV?

Do analysts rate TTRX or MNOV?

Is TTRX or MNOV more profitable?

Summary

How does MediciNova compare to Amarin?

Does the media favor AMRN or MNOV?

Which has more risk & volatility, AMRN or MNOV?

Is AMRN or MNOV more profitable?

Which has preferable valuation & earnings, AMRN or MNOV?

Do institutionals & insiders hold more shares of AMRN or MNOV?

Do analysts recommend AMRN or MNOV?

Summary

How does MediciNova compare to Zentalis Pharmaceuticals?

Is ZNTL or MNOV more profitable?

Which has stronger earnings and valuation, ZNTL or MNOV?

Which has more volatility & risk, ZNTL or MNOV?

Do insiders & institutionals hold more shares of ZNTL or MNOV?

Do analysts prefer ZNTL or MNOV?

Does the media favor ZNTL or MNOV?

Summary

How does MediciNova compare to Aurora Cannabis?

Which has stronger earnings and valuation, ACB or MNOV?

Which has more volatility & risk, ACB or MNOV?

Does the media favor ACB or MNOV?

Do analysts prefer ACB or MNOV?

Is ACB or MNOV more profitable?

Do insiders & institutionals hold more shares of ACB or MNOV?

Summary

How does MediciNova compare to Cardiol Therapeutics?

Which has higher earnings & valuation, CRDL or MNOV?

Does the media favor CRDL or MNOV?

Is CRDL or MNOV more profitable?

Which has more volatility and risk, CRDL or MNOV?

Do analysts recommend CRDL or MNOV?

Do insiders & institutionals have more ownership in CRDL or MNOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools